Business Context and Reporting Period
This Form 8-K Current Report was filed by Korro Bio, Inc. (KRRO) on February 11, 2025. The filing addresses a change in executive leadership effective February 11, 2025, specifically regarding the temporary medical leave of the Chief Financial Officer and the appointment of interim successors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Departure of CFO: Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer), is taking a temporary medical leave of absence effective February 11, 2025.
- Interim Appointments:
- Dr. Ram Aiyar, President and CEO, has been appointed as interim principal financial officer.
- Mr. Oliver Dolan, Senior Vice President, Finance, has been appointed as interim principal accounting officer.
- Compensation: Dr. Aiyar will not receive additional compensation for the interim role. Mr. Dolan's appointment is in addition to his current duties.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks beyond the operational impact of the CFO's temporary absence. Management has ensured continuity by assigning interim roles to existing senior executives. Mr. Dolan brings prior experience from Unity Biotechnology, Haven Healthcare, and Compass Therapeutics and holds an MBA from MIT Sloan and is a licensed CPA.
Investor Verification Checklist
- Confirm the expected duration of Vineet Agarwal's medical leave and the timeline for a permanent CFO replacement.
- Review the company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Verify that no other undisclosed executive departures or governance issues are pending.
- Monitor future filings for any changes to the interim leadership structure or compensation arrangements.